• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A Commentary on "Comparative Analysis of Romosozumab Versus Vertebroplasty With Denosumab: Efficacy, Safety, and Secondary Bone Mineral Density Outcomes".

作者信息

Inui Toshihiko

机构信息

Department of Neurosurgery, Kotobuki Social Medical Corporation, Tominaga Hospital, Osaka, Japan.

出版信息

Neurospine. 2025 Mar;22(1):78-80. doi: 10.14245/ns.2550298.149. Epub 2025 Mar 31.

DOI:10.14245/ns.2550298.149
PMID:40211518
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12010862/
Abstract
摘要

相似文献

1
A Commentary on "Comparative Analysis of Romosozumab Versus Vertebroplasty With Denosumab: Efficacy, Safety, and Secondary Bone Mineral Density Outcomes".关于“罗莫佐单抗与地诺单抗椎体成形术的比较分析：疗效、安全性及继发性骨密度结果”的述评
Neurospine. 2025 Mar;22(1):78-80. doi: 10.14245/ns.2550298.149. Epub 2025 Mar 31.
2
Comparative Analysis of Romosozumab Versus Vertebroplasty With Denosumab: Efficacy, Safety, and Secondary Bone Mineral Density Outcomes.罗莫单抗与地诺单抗联合椎体成形术的对比分析：疗效、安全性及继发性骨矿物质密度结果
Neurospine. 2025 Mar;22(1):69-77. doi: 10.14245/ns.2449228.614. Epub 2025 Mar 31.
3
Romosozumab efficacy and safety in European patients enrolled in the FRAME trial.FRAME 试验中纳入的欧洲患者的 Romosozumab 疗效和安全性。
Osteoporos Int. 2022 Dec;33(12):2527-2536. doi: 10.1007/s00198-022-06544-2. Epub 2022 Sep 29.
4
Meta-analysis of the effects of denosumab and romosozumab on bone mineral density and turnover markers in patients with osteoporosis.骨质疏松症患者 denosumab 和 romosozumab 对骨密度和骨转换标志物影响的荟萃分析。
Front Endocrinol (Lausanne). 2023 Jul 12;14:1188969. doi: 10.3389/fendo.2023.1188969. eCollection 2023.
5
Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension.在 FRAME 关键性试验及其扩展研究的日本亚组中，与安慰剂相比，罗莫佐单抗治疗 1 年可增加骨密度，随后用地舒单抗治疗 2 年。
Arch Osteoporos. 2019 Jun 5;14(1):59. doi: 10.1007/s11657-019-0608-z.
6
Verification of efficacy and safety of ibandronate or denosumab for postmenopausal osteoporosis after 12-month treatment with romosozumab as sequential therapy: The prospective VICTOR study.罗莫佐单抗序贯治疗 12 个月后伊班膦酸盐或地舒单抗治疗绝经后骨质疏松症的疗效和安全性验证：前瞻性 VICTOR 研究。
Bone. 2022 Sep;162:116480. doi: 10.1016/j.bone.2022.116480. Epub 2022 Jul 1.
7
One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study.罗莫佐单抗治疗 1 年后序贯地舒单抗治疗 2 年可维持骨折风险降低：FRAME 扩展研究结果。
J Bone Miner Res. 2019 Mar;34(3):419-428. doi: 10.1002/jbmr.3622. Epub 2018 Dec 3.
8
Denosumab versus romosozumab for postmenopausal osteoporosis treatment.地舒单抗与罗莫佐单抗治疗绝经后骨质疏松症。
Sci Rep. 2021 Jun 3;11(1):11801. doi: 10.1038/s41598-021-91248-6.
9
Verifying the effectiveness of romosozumab re-administration on bone mineral density.验证罗莫佐单抗再次给药对骨密度的有效性。
J Bone Miner Res. 2025 Feb 2;40(2):201-210. doi: 10.1093/jbmr/zjae196.
10
Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study.罗莫佐单抗治疗 24 个月后序贯地舒单抗或安慰剂治疗 12 个月对骨密度低的绝经后妇女的影响：一项随机、双盲、2 期、平行组研究。
J Bone Miner Res. 2018 Aug;33(8):1397-1406. doi: 10.1002/jbmr.3452. Epub 2018 May 22.

本文引用的文献

1
Comparative Analysis of Romosozumab Versus Vertebroplasty With Denosumab: Efficacy, Safety, and Secondary Bone Mineral Density Outcomes.罗莫单抗与地诺单抗联合椎体成形术的对比分析：疗效、安全性及继发性骨矿物质密度结果
Neurospine. 2025 Mar;22(1):69-77. doi: 10.14245/ns.2449228.614. Epub 2025 Mar 31.
2
Comparison of the Clinical Efficacy of Anabolic Agents and Bisphosphonates in the Patients With Osteoporotic Vertebral Fracture: Systematic Review and Meta-analysis of Randomized Controlled Trials.合成代谢药物与双膦酸盐治疗骨质疏松性椎体骨折患者的临床疗效比较：随机对照试验的系统评价与Meta分析
Neurospine. 2024 Jun;21(2):416-429. doi: 10.14245/ns.2347256.628. Epub 2024 May 2.
3
Comparison of the Efficacy of Romosozumab and Teriparatide for the Management of Osteoporotic Vertebral Compression Fractures.罗莫单抗与特立帕肽治疗骨质疏松性椎体压缩骨折的疗效比较
Neurospine. 2023 Dec;20(4):1217-1223. doi: 10.14245/ns.2347030.515. Epub 2023 Dec 31.
4
Romosozumab versus Teriparatide for the Treatment of Postmenopausal Osteoporosis: A Systematic Review and Meta-analysis through a Grade Analysis of Evidence.罗莫佐单抗与特立帕肽治疗绝经后骨质疏松症：通过证据分级分析的系统评价和荟萃分析。
Orthop Surg. 2021 Oct;13(7):1941-1950. doi: 10.1111/os.13136. Epub 2021 Oct 12.
5
Vertebroplasty versus sham procedure for painful acute osteoporotic vertebral compression fractures (VERTOS IV): randomised sham controlled clinical trial.椎体成形术与假手术治疗疼痛性急性骨质疏松性椎体压缩性骨折（VERTOS IV）：随机假手术对照临床试验。
BMJ. 2018 May 9;361:k1551. doi: 10.1136/bmj.k1551.
6
Percutaneous vertebroplasty for osteoporotic vertebral compression fracture.经皮椎体成形术治疗骨质疏松性椎体压缩骨折
Cochrane Database Syst Rev. 2018 Apr 4;4(4):CD006349. doi: 10.1002/14651858.CD006349.pub3.
7
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.罗莫佐单抗或阿仑膦酸钠用于预防骨质疏松症女性骨折。
N Engl J Med. 2017 Oct 12;377(15):1417-1427. doi: 10.1056/NEJMoa1708322. Epub 2017 Sep 11.
8
Romosozumab Treatment in Postmenopausal Women with Osteoporosis.罗莫佐单抗治疗绝经后骨质疏松症妇女。
N Engl J Med. 2016 Oct 20;375(16):1532-1543. doi: 10.1056/NEJMoa1607948. Epub 2016 Sep 18.
9
Predicting delayed union in osteoporotic vertebral fractures with consecutive magnetic resonance imaging in the acute phase: a multicenter cohort study.急性期连续磁共振成像预测骨质疏松性椎体骨折的骨不连：一项多中心队列研究。
Osteoporos Int. 2016 Dec;27(12):3567-3575. doi: 10.1007/s00198-016-3687-3. Epub 2016 Jun 25.